CVS Health Corporation $CVS Shares Acquired by Czech National Bank

Czech National Bank lifted its holdings in shares of CVS Health Corporation (NYSE:CVS) by 4.8% in the second quarter, HoldingsChannel reports. The firm owned 363,178 shares of the pharmacy operator’s stock after acquiring an additional 16,697 shares during the period. Czech National Bank’s holdings in CVS Health were worth $37,571,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in CVS Health during the 4th quarter valued at $1,666,265,000. Wellington Management Group LLP raised its holdings in shares of CVS Health by 193.2% in the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after acquiring an additional 12,233,675 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of CVS Health by 1,020.7% in the first quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator’s stock valued at $347,984,000 after acquiring an additional 4,412,882 shares in the last quarter. Amundi boosted its stake in shares of CVS Health by 95.3% during the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after acquiring an additional 3,637,943 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in CVS Health by 44.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock worth $446,703,000 after purchasing an additional 1,899,932 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the sale, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders sold 3,372,000 shares of company stock valued at $317,473,598. Insiders own 0.85% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. All three major segments—Aetna insurance, pharmacy services and health services—contributed to the result. CVS blows past estimates, hikes guidance as insurance unit continues to improve
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50 and increased operating cash-flow guidance to at least $11.5 billion. Improved medical-cost performance at Aetna, stronger drug revenue and a more profitable pharmacy mix supported the outlook. CVS Health reports strong second-quarter results and raises full-year guidance
• Positive Sentiment: CVS also expanded its weight-management strategy through a collaboration with Eli Lilly, offering additional access to Zepbound and other GLP-1 treatments through CVS Pharmacy and its digital care platform. The initiative could support pharmacy traffic and future growth. CVS Health enhances direct-to-consumer weight-management offerings
• Neutral Sentiment: The improving Aetna Medicare Advantage business is a key turnaround catalyst, but management’s commentary suggests the recovery is still being evaluated against changing healthcare costs and reimbursement conditions. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks
• Negative Sentiment: Investors remain concerned about 2027 pressure on Caremark from potential 340B program changes and declining membership. Those risks could offset current insurance improvements and help explain why the stock fell despite the earnings beat and higher 2026 outlook. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Sanford C. Bernstein boosted their target price on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Morgan Stanley lifted their price target on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Barclays boosted their price objective on shares of CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday. Robert W. Baird set a $107.00 price objective on shares of CVS Health in a research note on Thursday. Finally, Wall Street Zen upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Thursday, July 23rd. Twenty-two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $106.46.

CVS Health Stock Down 2.8%

Shares of CVS opened at $96.32 on Friday. CVS Health Corporation has a fifty-two week low of $62.55 and a fifty-two week high of $110.68. The company’s fifty day moving average is $102.17 and its two-hundred day moving average is $87.68. The firm has a market cap of $122.90 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same period last year, the company posted $1.81 EPS. The business’s quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Analysts forecast that CVS Health Corporation will post 8 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is 70.37%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.